» Articles » PMID: 36749635

Late Gene Expression-deficient Cytomegalovirus Vectors Elicit Conventional T Cells That Do Not Protect Against SIV

Abstract

Rhesus cytomegalovirus-based (RhCMV-based) vaccine vectors induce immune responses that protect ~60% of rhesus macaques (RMs) from SIVmac239 challenge. This efficacy depends on induction of effector memory-based (EM-biased) CD8+ T cells recognizing SIV peptides presented by major histocompatibility complex-E (MHC-E) instead of MHC-Ia. The phenotype, durability, and efficacy of RhCMV/SIV-elicited cellular immune responses were maintained when vector spread was severely reduced by deleting the antihost intrinsic immunity factor phosphoprotein 71 (pp71). Here, we examined the impact of an even more stringent attenuation strategy on vector-induced immune protection against SIV. Fusion of the FK506-binding protein (FKBP) degradation domain to Rh108, the orthologue of the essential human CMV (HCMV) late gene transcription factor UL79, generated RhCMV/SIV vectors that conditionally replicate only when the FK506 analog Shield-1 is present. Despite lacking in vivo dissemination and reduced innate and B cell responses to vaccination, Rh108-deficient 68-1 RhCMV/SIV vectors elicited high-frequency, durable, EM-biased, SIV-specific T cell responses in RhCMV-seropositive RMs at doses of ≥ 1 × 106 PFU. Strikingly, elicited CD8+ T cells exclusively targeted MHC-Ia-restricted epitopes and failed to protect against SIVmac239 challenge. Thus, Rh108-dependent late gene expression is required for both induction of MHC-E-restricted T cells and protection against SIV.

Citing Articles

Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.

Bruton J, Hanke T Vaccines (Basel). 2025; 13(1).

PMID: 39852851 PMC: 11769474. DOI: 10.3390/vaccines13010072.


Proceedings of the Conference "CMV Vaccine Development-How Close Are We?" (27-28 September 2023).

Schleiss M, Crooks C, Karthigeyan K, Kruc R, Otero C, Wang H Vaccines (Basel). 2024; 12(11).

PMID: 39591134 PMC: 11598149. DOI: 10.3390/vaccines12111231.


Human cytomegalovirus UL18 prevents priming of MHC-E- and MHC-II-restricted CD8 T cells.

Malouli D, Taher H, Mansouri M, Iyer R, Reed J, Papen C Sci Immunol. 2024; 9(100):eadp5216.

PMID: 39392895 PMC: 11797217. DOI: 10.1126/sciimmunol.adp5216.


Viral escape mutations do not account for non-protection from SIVmac239 challenge in RhCMV/SIV vaccinated rhesus macaques.

Bimber B, Sunshine J, McElfresh G, Reed J, Pathak R, Bateman K Front Immunol. 2024; 15:1444621.

PMID: 39170621 PMC: 11336698. DOI: 10.3389/fimmu.2024.1444621.


Metagenomic comparison of intestinal microbiota between normal and liver fibrotic rhesus macaques (Macaca mulatta).

Wei Y, Li J, Zhu B, Hu Q, Lan M, Zhou J Sci Rep. 2024; 14(1):15677.

PMID: 38977718 PMC: 11231266. DOI: 10.1038/s41598-024-64397-7.


References
1.
Malouli D, Hansen S, Hancock M, Hughes C, Ford J, Gilbride R . Cytomegaloviral determinants of CD8 T cell programming and RhCMV/SIV vaccine efficacy. Sci Immunol. 2021; 6(57). PMC: 8244349. DOI: 10.1126/sciimmunol.abg5413. View

2.
Hansen S, Ford J, Lewis M, Ventura A, Hughes C, Coyne-Johnson L . Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473(7348):523-7. PMC: 3102768. DOI: 10.1038/nature10003. View

3.
Hansen S, Piatak Jr M, Ventura A, Hughes C, Gilbride R, Ford J . Immune clearance of highly pathogenic SIV infection. Nature. 2013; 502(7469):100-4. PMC: 3849456. DOI: 10.1038/nature12519. View

4.
Hansen S, Zak D, Xu G, Ford J, Marshall E, Malouli D . Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. Nat Med. 2018; 24(2):130-143. PMC: 5909823. DOI: 10.1038/nm.4473. View

5.
Bowman J, Lacayo J, Burbelo P, Fischer E, Cohen J . Rhesus and human cytomegalovirus glycoprotein L are required for infection and cell-to-cell spread of virus but cannot complement each other. J Virol. 2010; 85(5):2089-99. PMC: 3067789. DOI: 10.1128/JVI.01970-10. View